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Abstract (222 words) 19 
Lyssavirus infection has a near 100% case fatality rate following the onset of clinical disease, 20 
and current rabies vaccines confer protection against all reported phylogroup I lyssaviruses. 21 
However, there is little or no protection against more divergent lyssaviruses and so 22 
investigation into epitopes within the glycoprotein (G) that dictate a neutralising response 23 
against divergent lyssaviruses is warranted. Importantly, the facilities required to work with 24 
these pathogens, including wildtype and mutated forms of different lyssaviruses are scarcely 25 
available and as such this type of study is inherently difficult to perform.  The relevance of 26 
proposed immunogenic antigenic sites within the lyssavirus glycoprotein was assessed by 27 
swapping sites between phylogroup-I and phylogroup-II glycoproteins. Demonstrable intra- 28 
but limited inter-phylogroup cross neutralisation was observed. Pseudotype viruses (PTVs) 29 
presenting a phylogroup-I glycoprotein containing phylogroup-II antigenic sites (I, II III or 30 
IV) were neutralised by antibodies raised against phylogroup-II PTV with the site II (IIb, aa 31 
34-42 and IIa, aa 198-200) swapped PTVs being efficiently neutralised whilst site IV 32 
swapped PTV was poorly neutralised.  The phylogroup-II glycoprotein specific antibodies 33 
raised against PTV containing antigenic site swaps between phylogroup-I and phylogroup-II 34 
glycoproteins neutralised phylogroup-I PTVs efficiently, indicating an immunodominance of 35 
antigenic site II.  Live-lyssaviruses containing antigenic site swapped glycoproteins were 36 
generated and indicated that specific residues within the lyssavirus glycoprotein dictate 37 







The lyssaviruses constitute virus genus of importance to both human and animal health. All 45 
viruses within this genus are highly neurotropic and are capable of causing a fatal disease 46 
resulting in encephalitis, known as rabies [1]. The lyssavirus genus is classified within the 47 
Order Mononegavirales, Family Rhabdoviridae and comprises 16 proposed species. 48 
Lyssaviruses have non-segmented (single-stranded) negative sense genomes of between 11-49 
12kbp. The genome encodes 5 proteins: the nucleocapsid (N) protein, the phosphoprotein (P), 50 
the matrix protein (M), the glycoprotein (G) and the large polymerase protein (L). The 51 
prototypic lyssavirus is rabies virus (RABV), which is primarily transmitted through the bite 52 
of an infected animal and causes a higher burden of disease in both humans and animals than 53 
any other lyssavirus. Members of the lyssavirus genus are able to infect and cause disease in 54 
a wide host range, with theoretically all mammalian species being susceptible to infection [2]. 55 
It is estimated that more than 60,000 people die from rabies annually [1, 3-5]. Despite safe 56 
and effective prophylactic and post-exposure tools being available RABV remains endemic 57 
across much of Africa and Asia. Fourteen of the 16 proposed lyssaviruses have been 58 
associated with the infection of bat species and chiropteran species are generally considered 59 
to be the reservoir for the lyssaviruses [6, 7]. Infection of humans with non-RABV 60 
lyssaviruses appears to be rare with only 13 human fatalities being documented [8]. 61 
 62 
Safe and effective RABV vaccines have been available for decades. These vaccines, 63 
generally based on inactivated preparations of classical RABV strains, can be used for both 64 
pre-exposure (PrEP) and post exposure prophylaxis (PEP). PrEP involves a course of 65 
parenteral vaccination according to internationally agreed guidelines that are considered 66 
sufficient to achieve an antibody titre of 0.5 IU/ml. This arbitrary value is set as the global cut 67 
off for antibody mediated protection against rabies [9]. Whilst highly effective against 68 
RABV, the ability of RABV vaccines to protect against other lyssaviruses is variable or 69 
undefined. As such, within the lyssavirus genus, viruses have been classified according to 70 
both genetic and antigenic data into phylogroups [10-14]. Phylogroup I includes the classical 71 
RABVs alongside Aravan lyssavirus (ARAV), Australian bat lyssavirus (ABLV), Bokeloh 72 
bat lyssavirus (BBLV), Duvenhage lyssavirus (DUVV), European bat -1 and -2 lyssaviruses 73 
(EBLV-1 and EBLV-2), Gannoruwa bat lyssavirus (GBLV), Irkut lyssavirus (IRKV) and 74 
Khujand lyssavirus (KHUV). Phylogroup II encompasses the African Lyssaviruses, namely 75 
Lagos bat lyssavirus (LBV-lineages A-D), Mokola lyssavirus (MOKV) and Shimoni bat 76 
lyssavirus (SHIBV) whilst phylogroup III has been proposed tentatively due to the 77 
divergence of the G and includes West Caucasian bat lyssavirus (WCBV) [13], Ikoma 78 
lyssavirus (IKOV) [8, 15] and a further, highly divergent lyssavirus, Lleida Bat Lyssavirus 79 
(LLEBV)  [16]. The differentiation of viruses into phylogroups is mainly based on the degree 80 
of protection afforded by the rabies vaccines against each of the viruses in animal models, 81 
although some cross neutralisation studies have also been performed. Limited studies have 82 
suggested that there is a low degree of cross neutralisation between phylogroups I and II and 83 
also between both phylogroups and WBCV [12]. In vivo vaccination-challenge experiments 84 
have shown reduced or no efficacy of current licensed rabies vaccines against viruses in 85 
phylogroup II (MOKV, LBV, SHIBV) [17] and phylogroup III viruses (WCBV, IKOV) [15, 86 
18, 19]. Evidence also exists for variable vaccine efficacy against phylogroup I lyssaviruses 87 
[18, 20-23], which suggests a reduction in vaccine protection that correlates with the 88 
antigenic distance of lyssavirus species from vaccine strains. This has most comprehensively 89 
been demonstrated using antigenic cartography as a mechanism to define the antigenic 90 
relationships between lyssaviruses and both post-vaccinal and lyssavirus-specific sera [12] 91 
 92 
The target for neutralising antibody responses against all lyssaviruses is the surface 93 
glycoprotein (G). This protein is the major viral component responsible for the induction of a 94 
host antibody response and is thought to be the sole target of host neutralising antibodies 95 
[24]. Studies with the RABV G protein have defined four major antigenic sites and one minor 96 
antigenic site [25-33]. These regions include four continuous epitopes and a discontinuous 97 
conformational epitope proposed to be formed through the interaction of two distinct regions 98 
(antigenic sites IIa and IIb) within the mature protein. The relative importance of each site for 99 
neutralisation of RABV has been previously measured using crude estimates of the number 100 
of monoclonal antibodies specific to each site, but not with polyclonal sera. Although 101 
important in RABV neutralisation, there is currently no evidence to suggest that the same 102 
regions have a similar function within the other lyssaviruses. Still, whilst there is no structural 103 
model for the lyssavirus glycoprotein, alignments with the Vesicular Stomatitis Virus pre- 104 
and post-fusion glycoprotein structures [34, 35] at least suggest that these antigenic sites are 105 
present on the exposed surfaces of the glycoprotein. However, the role of these antigenic sites 106 
is undefined, hampering assessment of the threat posed by emerging lyssaviruses, and 107 
vaccine design. In this study, the importance of these RABV antigenic epitopes for virus 108 
neutralisation across the lyssavirus genus was assessed, using data from both pseudotype 109 
viruses and recombinant lyssaviruses generated by reverse genetics. This study demonstrates 110 
that individual antigenic sites are highly specific in generating the differential neutralisation 111 
pattern seen between the proposed lyssavirus phylogroups against the lyssavirus G protein. 112 
 113 
Results 114 
All phylogroup I PTVs are neutralised by sera derived from canine and human vaccinees. 115 
To assess the ability of sera from vaccinated humans and animals to neutralise all viruses 116 
within phylogroup I, a panel of PTVs was generated to enable the assessment of a 117 
representative of each lyssavirus species. Two types of RABV specific sera were assessed 118 
against this panel: WHO serum, an international standard sera prepared from blood sampled 119 
from vaccinated humans that is used as control sera for WHO gold standard serological 120 
assays; and Veterinary Laboratories Agency (VLA) serum, a diagnostic control serum 121 
obtained from a pool of serum from vaccinated dogs used in serological diagnostic tests 122 
performed at APHA, UK. Both sera were used at a dilution of 0.5 IU/ml, the WHO and OIE 123 
internationally accepted cut-off titre for seroconversion [9] and a more stringent threshold of 124 
0.1 IU/ml according to dilutions assessed using live virus in the Fluorescent Antibody Virus 125 
Neutralisation test (FAVN). The PNA was used to assess the ability of WHO and VLA sera 126 
to neutralise each phylogroup I PTV (Figure 1) and all were neutralised by >90% by these 127 
sera. Furthermore, all of the phylogroup I PTVs were also completely neutralised by WHO 128 
and VLA sera at 0.1 IU/ml. (Supplementary Figure 1).  129 
 130 
A humoral response to phylogroup II lyssaviruses neutralises other phylogroup II PTVs  131 
To investigate the degree of cross neutralisation between viruses within phylogroup II, 132 
specific sera had to be generated specific for phylogroup II. A PTV expressing LBV lineage 133 
B G was selected for inoculation into rabbits to generate sera specific for this G protein. 134 
Representative PTVs for all available lyssavirus phylogroups were successfully generated. 135 
Dilution of LBV lineage B sera to a neutralising concentration approximately equal to the 136 
0.5IU/ml cut off assigned to seroconversion was performed using a modified version of the 137 
FAVN with homologous live LBV lineage B and was expressed as reciprocal titre. This 138 
serum demonstrated a strong degree of cross neutralisation within the phylogroup (Figure 2) 139 
as had previously been demonstrated for viruses within phylogroup I [22]. Because LBV 140 
lineage A, C and D sera were unavailable, investigation into the neutralisation of LBV 141 
isolates was limited to LBV lineage B specific serum. The LBV B serum was able to 142 
neutralise the three LBV PTVs tested as well as a representative MOK and SHIBV PTV to 143 
>90%. LBV serum demonstrated a lower degree of neutralisation of WCBV and IKOV PTVs 144 
with values of 27% and 60%, respectively.  145 
 146 
Alterations to antigenic domains within the lyssavirus G affect both functionality and 147 
neutralisation profiles of the mutated proteins. 148 
To further investigate the relative importance  the five defined antigenic epitopes, a series of 149 
recombinant PTVs were developed that had the defined antigenic epitopes swapped between 150 
a phylogroup I virus (CVS) and a phylogroup II virus (LBV lineage B). Both individual 151 
antigenic site mutants [36] were utilised alongside G proteins that had all five antigenic 152 
epitopes exchanged between the two viruses (Figure 3). Once plasmids had been constructed, 153 
the ability to generate PTs with each of the single site swaps (SSS) was assessed alongside 154 
the ability to generate the full site swap (FSS) mutants. Initially, functionality of mutated 155 
forms of the G protein were assessed through their relative ability to generate titres as PTVs. 156 
Then, where titres were achieved, the ability of standard sera to neutralise these recombinant 157 
PTVs were assayed. All attempts to generate a PTV containing the CVS G with all five 158 
antigenic sites being swapped with those of LBV (CVSFSS) failed to generate titres of 200 159 
TCID50/ml and so could not be used in the PNA.  160 
 161 
The WHO, VLA and LBV lineage B sera described earlier were next used to assess the 162 
antigenic effect of the site swaps. All CVS based PTVs including the CVS wildtype PTV 163 
were almost completely neutralised by both serum samples specific for RABV. The CVS 164 
wildtype PTV was not neutralised by the LBV B serum, however a number of single and 165 
multiple antigenic site swap mutants were neutralised by the LBV B specific sera, with those 166 
mutants containing the LBV site II epitope(s) being most strongly affected (Supplementary 167 
Figure 2). CVS to LBV IIb was neutralised by 98% whilst CVS to LBV IIaIIb and CVS to 168 
LBV IIa were neutralised by 80% and 65%, respectively. Alterations to sites I and III also 169 
affected the neutralisation profiles observed although to a lesser extent. The exchange of site 170 
IV had little effect on the neutralisation profiles observed.  171 
 172 
The reciprocal assay was performed with the LBV to CVS antigenic site swaps, again 173 
utilising the same panel of sera described previously (Supplementary Figure 3).  The LBV B 174 
wildtype PTV was neutralised by the LBV B specific sera although neutralisation of the LBV 175 
B wildtype PTV was also observed with the RABV specific sera. Furthermore, the LBVFSS 176 
PTV containing all of the antigenic epitopes of CVS was neutralised by both the RABV and 177 
LBV specific sera.  Each of the single site swap PTVs were neutralised by the LBV specific 178 
sera although some of the mutants, LBV to CVS sites I, IIb, IIaIIb and III,  were neutralised 179 
to a greater degree by the RABV sera than the LBV sera suggesting that these epitopes may 180 
play more prominent roles in neutralisation. 181 
 182 
Sera generated against mutated PTVs demonstrated differential neutralisation of wildtype 183 
PTVs  184 
To further investigate the role of antigenic epitopes in the G protein, a series of mutated and 185 
wildtype PTVs were inoculated into rabbits to generate sera specific for each mutant. Four 186 
mutant PTVs were selected, CVS to LBV I, LBV to CVS I, LBV to CVS IIaIIb and 187 
LBVFSS, on the basis of earlier results. The CVS to LBV I, LBV to CVS I, LBV to CVS 188 
IIaIIb and LBVFSS specific sera were run against wildtype CVS and LBV PTVs at 0.5 IU/ml 189 
(Figure 4). The CVS to LBV I serum neutralised the CVS PTV but also neutralised the LBV 190 
PTV by 47%. In the reciprocal experiment the LBV to CVS I serum completely neutralised 191 
the LBV PTV but only neutralised the CVS PTV by 7%.  Interestingly, the LBV to CVS 192 
IIaIIb serum neutralised the CVS PTV more strongly than the LBV PTV; by 93% and 64%, 193 
respectively. Finally, the LBVFSS specific serum neutralised both CVS and LBV PTVs to a 194 
similar extent; 51% and 56% respectively. 195 
 196 
Mutations to antigenic sites within the wildtype glycoproteins affect virus rescue 197 
The observation that the CVSFSS PTV could not be generated, even following back mutation 198 
of sites IIa and IIb, led to speculation that the mutations incorporated into the glycoprotein 199 
had rendered it non-functional. Interestingly, the LBVFSS PTV could be generated and 200 
sufficient PTV titre reached to perform the PNA. To further investigate glycoprotein 201 
functionality following mutation a panel of full length clones was generated using a SAD 202 
B19 vaccine strain plasmid backbone [37, 38] with the wildtype glycoprotein gene being 203 
replaced with the mutated versions described for the PTVs. Despite repeated rescue attempts 204 
varying plasmid concentration, transfection reagent:DNA ratios and cell confluency the cSN-205 
CVSFSS plasmid failed to generate live virus that could be passaged in vitro. In contrast the 206 
cSN, cSN-CVS, and cSN-LBVFSS constructs produced viable virus and the expression of N 207 
was assessed by direct immunofluorescence (Data not shown). These three viruses were 208 
passed until confluency was achieved. Whilst the cSN and cSN-CVS virus reached 100% 209 
confluency after only 5 passages, the cSN-LBVFSS virus appeared restricted in growth and 210 
was unable to generate extensive foci of infection even after 10 passages.  211 
 212 
A multistep growth curve with rescued viruses demonstrated a reduction in titre in the 213 
recombinant viruses compared with cSN; cSN reached a peak titre of 8.35x108 ffu/ml at 72 214 
hours post infection (hpi) whilst cSN-CVS grew maximally to 5.84x103 ffu/ml (Figure 5). 215 
cSN-LBVFSS was detected from 24 hpi at a very low level of 4.85x101 ffu/ml but could not 216 
be detected at 96 hpi.  217 
 218 
Assessment of vaccine protection and pathogenicity of recombinant viruses in the murine 219 
model 220 
Considering the effect of antigenic site swaps on fitness in vitro, it was important and 221 
relevant to vaccine design to assess their pathogenesis in vivo. Both peripheral pathogenesis 222 
experiments and vaccination challenge experiments were undertaken. To assess peripheral 223 
pathogenicity in unvaccinated mice, groups of naïve mice were inoculated peripherally via 224 
the intramuscular route. Previous studies have demonstrated that to demonstrate 225 
pathogenicity in this mouse breed following intramuscular peripheral inoculation at least 226 
1000ffu/50µl is required (unpublished data). Therefore, cSN and cSN-CVS were both 227 
inoculated at 1000ffu/50µl. However, despite repeated passages and attempts to concentrate 228 
the virus, the titre of cSN-LBVFSS could not be increased above 200ffu/50µl and so this 229 
dose was inoculated peripherally. To control for cSN-LBVFSS, a group of mice were 230 
peripherally inoculated with 1000ffu/50µl of a wildtype LBV lineage B. All peripherally 231 
inoculated mice survived infection with the exception of those inoculated with cSN-CVS 232 
where 40% succumbed on day 8 post infection and the wildtype LBV isolate where 20% 233 
developed clinical disease at 8 days post infection (Figure 6a). Of those that survived 234 
infection, 60% of the cSN-LBVFSS peripherally infected mice generated a serological 235 
response of >0.5IU/ml. All unvaccinated mice infected with LBV seroconverted strongly 236 
against LBV and 50% (n=2/4) had a low neutralising titre against CVS (Figure 7). 237 
 238 
For assessment of vaccine protection, four groups of mice (n=10/group) were vaccinated and 239 
challenged on day 28 post vaccination. Four groups of 5 mice were mock vaccinated with 240 
phosphate buffered saline (PBS) using the same vaccination schedule. All vaccinated mice 241 
seroconverted with reciprocal titres equal to or greater than the WHO 0.5IU/ml control serum 242 
by FAVN (data not shown) and a pool of sera from mock vaccinated mice had a titre that 243 
indicated serological naïvety in unvaccinated animals. 244 
 245 
Unvaccinated mice inoculated with either 100ffu/30µl of cSN or cSN-CVS via the IC route 246 
developed clinical disease consistent with lyssavirus infection at 7 days post infection (Figure 247 
6b). Unvaccinated mice inoculated with 100ffu/30µl of cSN-LBVFSS did not develop 248 
clinical disease throughout the duration of the experiment. All unvaccinated mice inoculated 249 
IC with 100ffu/30µl of wildtype LBV, succumbed by day 7 post infection.  250 
 251 
All vaccinated mice survived IC inoculation with cSN and cSN-CVS. Of the vaccinated mice 252 
that were challenged with LBV, 80% succumbed to infection between days 7 and 9 (Figure 253 
6c). The two remaining LBV vaccinated mice survived up the end of the experiment and 254 
strongly seroconverted against both CVS and LBV with high virus neutralisation reciprocal 255 
titres against both LBV and CVS (data not shown). No mice challenged IC with 100ffu/30µl 256 
of cSN-LBVFSS developed clinical disease. However, from the cSN-LBVFSS challenged 257 
mice, all mock vaccinated, vaccinated and peripherally challenged unvaccinated mice 258 
seroconverted with very high serological responses to CVS (Figure 7). In contrast none of 259 
these mice generated serological responses capable of neutralising LBV (data not shown). 260 
 261 
Quantifying the antigenic effect of known antigenic sites 262 
The antigenic relationships of CVS, LBV and LBVFSS recombinant viruses are illustrated in 263 
the antigenic map (Figure 8). The positions of CVS and LBV correspond to those determined 264 
previously, with CVS close to but distinct from other RABVs and LBV antigenically distant 265 
from all other lyssavirus species [12]. Previous studies have demonstrated that substitution of 266 
the complete glycoproteins between different lyssaviruses causes a complete shift in 267 
antigenic phenotype to that of the G protein [38]. The antigenic mapping performed here has 268 
demonstrated that although swapping all previously defined major antigenic sites (LBVFSS) 269 
in G has had a significant effect on the antigenic phenotype of the resulting virus, it has not 270 
caused a complete phenotypic switch as seen with a replacement of the wildtype G. LBV 271 
with antigenic sites of CVS (LBVFSS) is positioned equidistant to the two wildtype viruses 272 
on which it is based (CVS and LBV). Relationships of sera raised against PTVs were also 273 
investigated using the same cartographical techniques (Figure 8). Serum raised against PTVs 274 
with only site I altered are close to the original or wildtype virus, whereas sera raised using a 275 
PTVs with site IIaIIb, and that with all sites substituted (FSS), are closer to the LBVFSS 276 
virus than to either CVS or LBV. Although it is not possible to account for individual 277 
variation in serological response with these single sera, these results suggest that site IIaIIb 278 




The absence of a crystal structure for the lyssavirus G precludes a thorough antigenic 283 
assessment of the lyssavirus G protein. Modelling the antigenic epitopes of lyssaviruses onto 284 
existing rhabdovirus G structures at least demonstrates that antigenic sites defined by 285 
monoclonal antibody typing for rabies are potentially located in exposed positions on the 286 
ectodomain of G [39] but this does not necessarily reflect the position or role of these regions 287 
in the mature native protein. As such the antigenic repertoire that precludes vaccine derived 288 
neutralisation for the lyssaviruses remains difficult to define.  289 
 290 
Data generated here using the PTV assay confirmed that cross neutralisation occurs within 291 
phylogroup I using standardised sera at both 0.5 IU and 0.1U/ml. This corroborates existing 292 
studies and suggests cross neutralisation within phylogroup I, both to a protective titre of 293 
anti-RABV serum but also to an apparently sub-protective but clearly neutralising dilution of 294 
serum. Previous studies have suggested that antibody titres lower than the internationally 295 
recognised cut-off (0.5IU/ml) are protective although test sensitivity makes a precise 296 
definition of this cut-off difficult [9, 40]. Regardless, varying levels of cross neutralisation 297 
within phylogroup I have been demonstrated previously whereby vaccination with the 298 
Human Diploid Culture Vaccine (HDCV) was able to protect more efficiently against CVS 299 
and EBLV-2 infection than ABLV or EBLV-1[21, 22]. Antigenic cartography has further 300 
enabled assessment of antigenicity and studies have suggested that ABLV and KHUV may 301 
be antigenically identical to the RABV isolates assessed. IRKV, ARAV and EBLV-1 are also 302 
believed to be closely related antigenically to RABV with EBLV-2 being more divergent 303 
amongst the isolates assessed [12]. Several studies have suggested a need for higher 304 
neutralising antibody titres to effectively neutralise non rabies phylogroup I lyssaviruses [22]. 305 
A single report of rabies vaccination protecting a dog from a phylogroup II virus exists 306 
whereby an animal vaccine, Rabiffa, appeared to protect dogs against challenge with LBV 307 
[20]. Observations of antigenic variation among phylogroup I viruses using live viruses, that 308 
contrast to studies with PTVs, may indicate disparity between the level of surface antigen 309 
presented on a PTV compared to a live virus. A PTV represents a pleiomorphic sack with 310 
unregulated amounts of G presented on is envelope in an uncontrolled manner. In contrast, 311 
the rhabdovirus virion represents a highly ordered bullet shaped virion with peplomers of 312 
trimeric G studded tightly across its surface. As such it is clear that the neutralisation of one 313 
is likely more readily achieved than the other. Certainly, this increased sensitivity of the PNA 314 
is something that has been observed before with influenza and lyssavirus PTVs [41, 42] and 315 
is something that should be considered when assessing neutralisation, especially where 316 
neutralisation reflects protection from the development of a fatal infection. Neutralisation 317 
profiles generated for neutralisation of PTVs using novel monoclonal antibodies have 318 
reiterated this [36]. Still, as previous studies have demonstrated that antibody responses to 319 
endogenous proteins within PTVs do not influence neutralisation of PTVs they can generally 320 
be considered a useful surrogate for neutralisation tests that avoid the use of live pathogen 321 
and have utility as vaccine candidates, although non-integrating PTV systems may be 322 
required to avoid potential safety concerns [43]. 323 
 324 
Although inter-phylogroup cross-neutralisation is not expected for the lyssaviruses, intra-325 
phylogroup neutralisation has not been assessed for all officially recognised lyssaviruses [17]. 326 
Sera from a group of Eidolon helvum fruit bats, a reservoir host for Lagos Bat Virus, 327 
appeared to be specific for lineage ‘A’ LBV with no neutralising activity against lineage B 328 
LBV [44]. In contrast, assessment of phylogroup II sera with a range of PTVs based on 329 
phylogroup II glycoproteins indicated a high degree of cross neutralisation within phylogroup 330 
II. The lyssavirus cross-reactivity conundrum is exacerbated by data from wild caught bats 331 
where sera have been suggested to be highly specific for individual lyssaviruses. Sera from 332 
76 insectivorous bats that reacted against WCBV were unable to neutralise other lyssaviruses, 333 
including LBV, MOKV, RABV and DUVV. Interestingly, a serum sample from a single bat 334 
also strongly neutralised DUVV [13]. Partial cross neutralisation of WCBV and IKOV by the 335 
LBV lineage B specific serum was observed in this study suggesting some cross 336 
neutralisation even where 54% (WCBV) and 48% (IKOV) amino acid identity is seen. 337 
Previous investigations indicated that antibodies induced by rabies vaccination provide no 338 
protection against infection with phylogroup II or III viruses, even at concentrations 20 times 339 
greater than those which neutralise phylogroup I constructs [18, 19]. This likely reflects that 340 
whilst PTVs have shown great utility in diverse applications, the amount of G presented on 341 
pleomorphic PTV particles in relation to that on naturally occurring virions requires further 342 
investigation and cross-neutralisation afforded by sera to live replication  competent viruses 343 
is required where isolates are available.  344 
 345 
The relative lack of inter-phylogroup neutralisation led to studies to investigate individual 346 
residues within the glycoprotein and their role in immunodominance. Understanding 347 
immunologically important domains has implications for assessing risk posed by emerging 348 
lyssaviruses, and for vaccine design. Historically, several immunodominant epitopes have 349 
been described for the rabies G protein and the role of these epitopes investigated. From the 350 
PNAs utilising PTVs containing Gs with individual site swaps, three antigenic sites were 351 
highlighted as being potentially important for both a phylogroup I and II neutralisation 352 
responses. The CVS to LBV site swap assay showed that antigenic site II mutants were most 353 
strongly neutralised by both RABV and LBV specific sera indicating the role site II in 354 
generating antibody response against LBV.  CVS PTVs containing LBV antigenic site II 355 
demonstrated the potential importance of this discontinuous conformational epitope. 356 
 357 
The reciprocal assay assessing LBV to CVS site swaps yielded a different pattern of 358 
neutralisation. The neutralisation of the wildtype LBV PTV, by both the VLA and WHO 359 
serum, was unexpected and may again reflect a lower density of G on the surface of PTV 360 
particles. This requires further investigation although rare instances of rabies vaccine 361 
protecting animals against LBV challenge have been described [20]. Interestingly, data from 362 
the individual site swap assay suggested that for the LBV to CVS site swaps, exchange of 363 
sites I and III did not affect neutralisation by any of the sera tested.  There is little evidence in 364 
the literature defining the importance of individual antigenic sites in lyssavirus neutralisation 365 
yet this study suggest that the generation of a neutralising response that neutralises 366 
phylogroup I lyssaviruses may rely on antibodies directed against antigenic sites I (aa 226-367 
231) and III (aa 330-338). In contrast the data suggests that neutralisation of phylogroup II 368 
viruses is more dependent on neutralising antibodies directed against antigenic site II (IIb, aa 369 
34-42; IIa, aa 198-200).  Previous studies have suggested that sites II and III are the most 370 
important for a CVS neutralising response in H-2d mice [26]. The importance of sites I,  II 371 
and III is also supported by the finding that a large number of neutralising anti-glycoprotein 372 
mAbs are specifically directed towards them [25].  373 
 374 
Antigenic cartography with polyclonal sera indicated that there are regions of the 375 
glycoprotein, outside of the established antigenic sites that may significantly affect 376 
antigenicity. The cSN-LBVFSS recombinant virus was positioned equidistant between the 377 
wildtype LBV and the wildtype RABVs on the antigenic map suggesting that the introduced 378 
mutations had affected the overall structure of the G protein and its ability to neutralise 379 
different lyssaviruses. This novel observation shows that the alteration of specific antigenic 380 
sites can be used to measure antigenic effects. Investigation into the neutralising capabilities 381 
of rabbit sera raised using site-directed-mutant viruses, suggested that the antigenic site 382 
swaps had altered the neutralisation. The CVS to LBV I serum versus the CVS PTV and the 383 
LBV PTV showed a very similar neutralisation profile to the reciprocal assay using the 384 
antigenic site swapped PTV whereas the LBV to CVS site I results were less similar, 385 
indicating LBV site I is more immunogenic than CVS site I. The CVS to LBV PTV panel 386 
(Supplementary Figure 2) suggested that sites I, III and IV were less important for 387 
neutralisation by serum specific to LBV B.  LBV to CVS I serum did not neutralise CVS 388 
PTV whereas the LBV B to CVS IIaIIb serum did (Figure 4). This suggests that site II is 389 
more important than site I in stimulating a specific antibody response. The LBVFSS serum 390 
was able to neutralise both CVS PTV and LBV PTV by approximately 50% (Figure 4) which 391 
was in contrast to the ability of both RABV and LBV specific sera to strongly neutralise 392 
LBVFSS PTV (Supplementary Figure 3). The differences between these neutralisation 393 
profiles may be due to individual differences in response to the antigens driven by innate 394 
differences between rabbit and mouse immune responses as the antigenic sites were 395 
originally mapped using murine antibodies [25]. Results may also be skewed through 396 
differences in the presentation of G in PTVs and further assessment with live viruses is 397 
warranted.  398 
 399 
Where functionality was assessed using recombinant viruses, the insertion of heterologous 400 
glycoproteins into the cSN backbone had affected the ability of the viruses to grow.  The 401 
complete failure of cSN-CVSFSS to rescue or grow to a detectable level mimicked attempts 402 
to produce the CVSFSS PTV. Both of these findings suggested that the mutations made to the 403 
antigenic sites had affected the functionality of this glycoprotein. Antigenic cartography 404 
corroborated the effect of antigenic site mutation with the positioning of sera and viruses on 405 
the map (Figure 8). The titres recorded correlated with the growth kinetics data (Figure 5) as 406 
cSN-LBVFSS had the slowest growth and the lowest peak titre likely mediated by the 407 
presence of heterologous M and G proteins present. The precise nature of interaction between 408 
the M and G remains undefined although for other viruses, interactions between homologous 409 
M and G are important [45-47]. For rabies G and M interactions drive optimal budding of 410 
nascent viral particles [48] with the cytoplasmic domain of the G protein  playing the key role 411 
in this interaction [45, 49]. The detrimental effect of replacing cSN G with a heterologous 412 
lyssavirus G was similar to findings from a previous study which incorporated the G proteins 413 
from EBLV-1 and EBLV-2 into cSN [38].  The molecular basis for this finding remains to be 414 
investigated and the effect of residue mutation on glycoprotein functionality requires further 415 
assessment.  416 
  417 
Vaccination challenge experimentation demonstrated that almost all mice that were mock 418 
vaccinated and challenged IC with recombinant viruses succumbed to infection and were 419 
humanely terminated by day 7 post infection (Figure 6a). The exception to this was the group 420 
of mice that received cSN-LBVFSS that survived the duration of the experiment. The 421 
seroconversion of the mock vaccinated cSN-LBVFSS challenged mice, the anamnestic 422 
response to cSN-LBVFSS challenge in vaccinated mice and the seroconversion of 60% of the 423 
unvaccinated, peripherally challenged mice suggests that despite poor in vitro growth, this 424 
virus was able to replicate in vivo but was likely cleared in the absence of a productive 425 
infection (Figure 7). Whilst all of these survivors seroconverted strongly against CVS, no 426 
serum neutralising titre was detected against LBV which may indicate a true dominance of 427 
the antigenic site(s) of CVS located within the chimeric LBVFSS glycoprotein. Conversely, 428 
50% of the mice peripherally infected with LBV seroconverted against both LBV and CVS 429 
whilst the remainder seroconverted against LBV but serum had no neutralising activity 430 
against CVS. This suggests the potential for variation in neutralising responses generated 431 
between animals. Whilst rarely reported, seroconversion in the absence of clinical disease has 432 
been demonstrated for lyssaviruses although mechanisms of viral clearance remain to be 433 
described [50]. 434 
 435 
The present study has indicated that: individual antigenic sites within the lyssavirus G can 436 
affect neutralisation profiles; pseudotype particles may be utilised as potential vaccine 437 
candidates but have limitations when assessing neutralising profiles; and importantly that 438 
immunodominant epitopes identified through monoclonal antibody mapping can differ when 439 
comparing responses to whole antigen in polyclonal sera. This latter point is of potential 440 
significance as the determination of immunodominant epitopes through monoclonal antibody 441 
binding is an artificial process in comparison to protein structure recognition by polyclonal 442 
sera. Certainly, it is likely that other, undefined immunologically important epitopes outside 443 
of those assessed here influence the repertoire of neutralising antibodies produced following 444 
vaccination. Regardless, the continued discovery of lyssaviruses that are genetically closely 445 
related to RABV [51] as well as those that are highly divergent [16] drives the need for 446 
further investigation into factors that contribute to a protective immune response across the 447 
genus. In conclusion, whilst rabies constitutes the biggest threat to human and animal health, 448 
the threat of lyssaviruses to human populations remains undefined and as such further studies 449 
that determine factors associated with cross-phylogroup neutralisation are warranted.  450 
 451 
Materials and Methods 452 
Cells Baby hamster kidney cells (BHK-21) and Human embryonic kidney cells (HEK 453 
293T/17) were grown and maintained as described previously [52]. All cell lines were 454 
maintained at 37°C in a 5% CO2 incubator (Binder). 455 
 456 
PTV plasmid construction, transfection, titration and neutralisation assays (PNA) 457 
Human immunodeficiency virus (HIV) based PTVs were generated using plasmid pI.18 that 458 
was prepared to accept insertion of lyssavirus glycoproteins following digestion by restriction 459 
enzymes [52]. Transfections were carried out with Lipofectamine LTX reagent (Invitrogen) 460 
according to the manufacturer’s instructions and as described previously [52]. The titres of 461 
harvested PTVs were determined by 50% tissue culture infective dose (TCID50) [52]. A 462 
negative cut off value was defined as the average cells alone luminescence multiplied by 2.5 463 
[52]. The last dilution at which all wells for each PTV were positive was used to determine 464 
the PTV titre in TCID50/ml calculated using the Spearman-Kärber method [53].  Reporter 465 
gene activity was measured on a Glomax 96 microplate luminometer (Promega) and for the 466 
percentage neutralisation test, the degree of neutralisation was calculated as a reduction in the 467 
level of luminescence compared to virus not exposed to serum. Each assay was carried out in 468 
triplicate and a mean average percentage neutralisation was calculated. For the serum titre 469 
test the 50% end point dilution (where complete neutralisation stopped in 50% of the wells) 470 
was also calculated using the Spearman-Kärber method [53]. Back titration of PTV was 471 
carried out alongside each PNA using the same method as that for initial titration to ensure 472 
consistent input of PTV. 473 
 474 
Full length plasmid construction Glycoproteins of interest were cloned into the cSN 475 
backbone, a reverse genetics system based on the SAD  B19 of rabies as described previously 476 
[38]. Constructs were generated including those containing swaps between phylogroups of all 477 
five antigenic epitopes, termed Full Site Swaps (FSS) (Figure 3).  The glycoprotein 478 
sequences of the rabies Challenge Virus Standard (CVS), CVSFSS and LBVFSS were each 479 
cloned into a vaccine strain backbone plasmid, cSN in place of its wildtype glycoprotein 480 
sequence. Primers to amplify different G open reading frames (ORFs) were generated to 481 
incorporate HpaI and NheI (Promega) restriction enzyme sites for downstream cloning into 482 
cSN.  Following ligation and transformation, clones were checked by restriction enzyme 483 
digestion and plasmid sequencing.  484 
 485 
Virus rescue, titration and growth curves Virus rescue was performed as described 486 
previously [38] using fowlpox T7 (FPT7) to provide sufficient T7 RNA polymerase. After 487 
one hour of incubation at 37°C the FPT7 was removed, the cells washed with PBS and each 488 
well was transfected with 1μg of pN, 1μg of pP, 1μg of pL and 2μg of genome plasmid using 489 
FuGENE6. Plates were incubated for 48-72 hours prior to harvest. Rescued virus was 490 
passaged until 100% infectivity was reached and titrated as previously described [54]. Virus 491 
titres were determined as focus forming units per ml (ffu/ml).  Multistep growth curves were 492 
conducted as previously described [38]. At each required time point, 100µl of supernatant 493 
was harvested, frozen at -80°C then thawed and titrated in triplicate on BHK cells. 494 
 495 
Ethics statement 496 
All studies involving animals were carried out within the appropriate high containment 497 
facilities at the Animal and Plant Health Agency (APHA), UK. All mouse and rabbit studies 498 
were conducted under HO project licenses PPL70/7394 and PPL 70/8275, respectively, 499 
following internal ethical review at APHA. All animals utilised in the study were given 500 
access to food and water ad libitum. 501 
 502 
Generation of PTV specific sera in rabbits A panel of PTVs containing wildtype or 503 
mutated lyssavirus G proteins was generated and inactivated by the addition of β-504 
propriolactone (1/4000 final dilution) and incubation at 4°C for 19 hours followed by 1 hour 505 
at 37°C. Aliquots of inactivated PTV were stored at -20°C until required. Each PTV was 506 
mixed with Montanide™ ISA 50 V2 (Seppic) at a 1:1 ratio prior to inoculation. One rabbit 507 
was inoculated per PTV. Prior to administration, inoculation sites were shaved and Emla 508 
cream (AstraZeneca) was applied. Each rabbit was inoculated at four sites subcutaneously 509 
followed by two sites intramuscularly on days 0, 21, 28 and 35. On day 43 all rabbits were 510 
anaesthetised and blood was removed via cardiac puncture under terminal anaesthesia. 511 
Following collection, blood was subjected to centrifugation at 2500 rpm (860 x g) for 10 512 
minutes, and cleared serum was harvested. Sera were heat inactivated at 56°C for 30 minutes 513 
then divided across 500µl aliquots and stored at -20°C until required. 514 
 515 
Murine studies 516 
Mice Three to four week old female CD1 mice (Charles River) were microchipped using 517 
Trovan chips to enable identification and housed as described above. 518 
 519 
Vaccination of mice The human rabies vaccine VeroRAB (Novartis) was reconstituted as 520 
per the manufacturer’s instructions in 1ml of sterile water immediately prior to vaccination of 521 
the mice. The reconstituted vaccine was diluted 1 in 20 in sterile filtered deionised water. 522 
Vaccine was introduced via intraperitoneal injection of 500µl to the lower right hand 523 
quadrant of the abdomen on days 0 and 14. 524 
 525 
Blood sampling by tail bleed At 21 days post vaccination the dorsal tail vein of each mouse 526 
was nicked under anaesthesia using a scalpel blade and blood was collected in CB 300 tubes 527 
(Sarstedt). Following collection, blood samples were stored at 4°C overnight prior to 528 
centrifugation at 2500 rpm (860 x g) for 10 minutes after which the serum was separated 529 
from the blood pellet. These serum samples were heat inactivated at 56°C for 30 minutes and 530 
stored at -20°C until required. 531 
 532 
Intracranial challenge with virus Mice were challenged intracranially with 100ffu/30µl of 533 
infectious recombinant virus. Following inoculation with live virus mice, were checked twice 534 
daily. Clinical scores were recorded for each mouse according to an established clinical score 535 
system with defined humane end points [55]. Any mice showing signs of clinical disease of 536 
score 3 were anaesthetised, blood collected by cardiac puncture and euthanised by cervical 537 
dislocation.  538 
 539 
Peripheral infection with virus Mice were inoculated into the footpad with 1000ffu/50μl of 540 
each virus under anaesthesia. Once anaesthetised, mice were placed into a holding container 541 
with a small hole, through which the left hind limb was extended to enable inoculation. Mice 542 
were monitored for 28 days post infection. Clinical signs were scored and mice terminated as 543 
described [55].  544 
 545 
Antigenic cartography Using techniques described previously [12, 56] an antigenic map 546 
was constructed illustrating the relationships of CVS, LBV and LBVFSS according to the 547 
titres of reference sera. Briefly; a target distance from a serum to each virus was derived by 548 
calculating the difference between the logarithm (log2) reciprocal neutralisation titre for that 549 
particular virus and the log2 reciprocal maximum titre achieved by that serum (against any 550 
virus). Antigenic cartography [56] implemented using ACMACS (www.antigenic-551 
cartography.org) was then used to optimise the positions of the viruses and sera relative to 552 
each other on a map, minimising the sum-squared error between map distance and target 553 
distance. 100 random restart optimisations created multiple maps which were ranked in order 554 
of total error and quantitatively compared to each other, and previous maps with the same 555 
viruses, for self-consistency. A total of 41 sera (37 control sera and four new sera generated 556 
in this study) were used to position the viruses on the map.  557 
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  697 
Figure legends 698 
Figure 1 Neutralisation profile of phylogroup I PTVs against 0.5 IU/ml RABV specific 699 
sera. WHO serum from vaccinated human and VLA serum from vaccinated dogs were 700 
diluted to 0.5 IU/ml. Error bars represent standard deviation about the mean of three replicate 701 
in-assay neutralisation tests. 702 
 703 
Figure 2 Cross neutralisation within a phylogroup II lyssavirus PTV panel.  PTV 704 
neutralisation assay. PTVs representing all members of phylogroup II plus phylogroup III 705 
WCBV and the highly divergent IKOV were run against an LBV lineage B PTV specific 706 
rabbit derived polyclonal serum diluted to 0.5 IU/ml. Error bars represent standard deviation 707 
about the mean of three replicate in-assay neutralisation tests. 708 
 709 
Figure 3 Schematic of the lyssavirus glycoprotein demonstrating the positions of defined 710 
antigenic sites. Glycoprotein monomers are shown with antigenic sites labelled. Examples 711 
given are: CVSFSS whereby genetic portions from CVS are shaded grey and the antigenic 712 
sites of LBV are white; The reciprocal, LBVFSS is shown with regions corresponding to 713 
CVS being white and the antigenic sites of LBV being shaded grey; and LBV-CVS IIaIIb 714 
whereby just CVS sites IIa and IIb are swapped into the LBV G. Defined antigenic sites are 715 
numbered following removal of the signal peptide. TM: transmembrane; NH2: amino 716 
terminus; COOH: Carboxyl-terminus. (Adapted from 39) 717 
 718 
Figure 4 Assessment of neutralisation profiles for sera derived from rabbits inoculated 719 
with antigenic mutant PTVs. The four sera directed against antigenic site swap mutants 720 
were diluted to 0.5 IU/ml and run against wildtype CVS and LBV PTVs. A 2-way ANOVA 721 
was used to determine any significant differences between neutralisation of each PTV by the 722 
test sera compared to the lack of neutralisation by negative dog serum (0% neutralisation by 723 
negative dog serum not shown). Significant differences are indicated by asterisks; *p≤0.05. 724 
Error bars represent standard deviation about the mean of three replicate in-assay 725 
neutralisation tests. 726 
 727 
Figure 5 Growth kinetics of recombinant lyssaviruses in vitro. Multiple step growth 728 
curves of each virus starting from MOI 0.01.  729 
 730 
Figure 6 In vivo assessment of recombinant viruses. (A) Survival curve of mice challenged 731 
peripherally. Each mouse was challenged with 1000ffu/50μl of virus via the foot pad, except 732 
the low titre cSN-LBVFSS which was inoculated neat at 200ffu/50μl. n = 5 per virus. (B) 733 
Survivorship of mock vaccinated (PBS) mice (n = 5/virus). Mice were infected with 734 
100ffu/30μl of virus via the intra cranial route. (C) Vaccinated mice were challenged with 735 
100 ffu/30μl of virus via the IC route on day 28 dost vaccination. Survivorship from day 28 736 
for 21 days is shown (n = 10 per virus). . 737 
 738 
Figure 7 Serological responses in mice inoculated with cSN-LBVFSS. Mock vaccinated 739 
(PBS) mice, vaccinated mice and unvaccinated peripherally challenged mice were assessed 740 
for serological responses to CVS. Neutralising antibody titre values are in IU/ml but plotted 741 
on a logarithmic scale for clarity. The defined 0.5IU/ml protective neutralising antibody titre 742 
is shown as a dotted line and is labelled on the y axis. 743 
 744 
Figure 8 Antigenic cartography demonstrating relative positioning of antigenic site 745 
mutant derived sera and viruses on a three dimensional map. Different coloured spheres 746 
represent viruses as labelled. The mutations incorporated into cSN-LBVFSS have altered its 747 
antigenicity, positioning it closer to CVS. Sera raised against single site mutants have also 748 
been displaced (labelled grey boxes).  749 
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 752 
Supplementary Figure 1 Neutralisation profile of phylogroup I PTVs against 0.1 IU/ml 753 
RABV specific sera. PTV neutralisation assay. WHO serum from vaccinated human and 754 
VLA serum from vaccinated dogs were diluted to 0.1 IU/ml. Error bars represent standard 755 
deviation about the mean of three replicate in-assay neutralisation tests. 756 
 757 
Supplementary Figure 2 CVS antigenic site swap PTV neutralisation profiles. The result 758 
of the CVS panel of antigenic site swap mutants PNA against both phylogroup I specific sera, 759 
WHO and VLA as well as phylogroup II specific sera, LBV. All sera were diluted to 0.5 760 
IU/ml. A two way ANOVA was used to determine significant differences between 761 
neutralisation of each PTV and neutralisation of CVS by its homologous WHO and VLA 762 
sera. Significance is indicated by an asterisk; *p≤0.05, **p≤0.005, ***p≤0.0001. Error bars 763 
represent standard deviation about the mean of three replicate in-assay neutralisation tests. 764 
 765 
Supplementary Figure 3 LBV antigenic site swap PTV neutralisation profiles. The result 766 
of the LBV panel of antigenic site swap mutants PNA against both phylogroup I specific sera, 767 
WHO and VLA as well as phylogroup II specific sera, LBV. All sera were diluted to 0.5 768 
IU/ml. Error bars represent standard deviation about the mean of three replicate in-assay 769 
neutralisation tests. 770 
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